Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.18 USD
Change Today +0.18 / 2.00%
Volume 4.8M
ARIA On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

ariad pharmaceuticals inc (ARIA) Snapshot

Open
$8.97
Previous Close
$9.00
Day High
$9.27
Day Low
$8.95
52 Week High
04/24/15 - $9.89
52 Week Low
10/13/14 - $4.90
Market Cap
1.7B
Average Volume 10 Days
3.2M
EPS TTM
$-0.88
Shares Outstanding
188.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARIAD PHARMACEUTICALS INC (ARIA)

ariad pharmaceuticals inc (ARIA) Related Businessweek News

No Related Businessweek News Found

ariad pharmaceuticals inc (ARIA) Details

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories. It also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, an orally active TKI for treating non-small cell lung cancer and various other solid tumors. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

379 Employees
Last Reported Date: 03/2/15
Founded in 1991

ariad pharmaceuticals inc (ARIA) Top Compensated Officers

Principal Founder, Chairman, Chief Executive ...
Total Annual Compensation: $1.4M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $676.0K
President of Research & Development and Chief...
Total Annual Compensation: $858.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $683.4K
Senior Vice President of Regulatory Affairs a...
Total Annual Compensation: $647.0K
Compensation as of Fiscal Year 2014.

ariad pharmaceuticals inc (ARIA) Key Developments

Ariad Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Ariad Pharmaceuticals Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $23,991,000 against $11,782,000 a year ago. Net loss was $52,676,000 or $0.28 basic and diluted per share against $49,822,000 or $0.27 basic and diluted per share a year ago. Net cash used in operating activities was $50,194,000 against $52,409,000 a year ago.

Ariad Pharmaceuticals Inc. Announces Management Changes

ARIAD Pharmaceuticals Inc. announced that founder, Harvey J. Berger, M.D., has informed the Board of Directors of his decision to retire as chairman and chief executive officer upon appointment of his successor or December 31, 2015, whichever is earlier. In addition, under the terms of the settlement, ARIAD’s Board has appointed Anna Protopapas by filling an existing open director seat on the Board. Sarissa will withdraw its proposed slate of director nominees, which included Ms. Protopapas, for election at the 2015 annual meeting and has agreed to vote all of its shares in favor of the Board’s nominees. Ms. Protopapas is Chief Executive Officer of Mersana Therapeutics. She previously served as a member of the Executive Committee of Takeda Pharmaceutical Company Limited and held various senior management positions, including President of Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda.

Ariad Pharmaceuticals Inc. to Report Q1, 2015 Results on May 07, 2015

Ariad Pharmaceuticals Inc. announced that they will report Q1, 2015 results at 9:00 AM, Eastern Standard Time on May 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARIA:US $9.18 USD +0.18

ARIA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $3.93 USD -0.06
Array BioPharma Inc $7.65 USD +0.01
Evotec AG €3.75 EUR -0.064
Insys Therapeutics Inc $59.60 USD -0.78
Pfizer Ltd/India 2,217 INR -2.75
View Industry Companies
 

Industry Analysis

ARIA

Industry Average

Valuation ARIA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.4x
Price/Book 44.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARIAD PHARMACEUTICALS INC, please visit www.ariad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.